Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?
File(s)
56197-PB3-7894-R3.pdf (564.32 KB)
Published version
Author(s)
Peng, Ling
Stebbing, Justin
Liang, Fei
Xia, Yang
Type
Journal Article
Date Issued
2021-08-30
Date Acceptance
2021-08-30
Citation
Translational Lung Cancer Research, 2021, 10 (9), pp.3858-3860
URI
URL
DOI
ISSN
2218-6751
Publisher
AME Publishing
Start Page
3858
End Page
3860
Journal / Book Title
Translational Lung Cancer Research
Volume
10
Issue
9
Copyright Statement
© Translational Lung Cancer Research. All rights reserved. This is an Open Access article
distributed in accordance with the Creative Commons
Attribution-NonCommercial-NoDerivs 4.0 International
License (CC BY-NC-ND 4.0), which permits the noncommercial replication and distribution of the article with
the strict proviso that no changes or edits are made and the
original work is properly cited (including links to both the
formal publication through the relevant DOI and the license).
See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
License URL
Sponsor
Imperial College Healthcare NHS Trust- BRC Funding
National Institute for Health Research
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000696884200001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Grant Number
RDB01 79560
NIHR-RP-011-053
Subjects
Science & Technology
Life Sciences & Biomedicine
Oncology
Respiratory System
1ST-LINE TREATMENT
PEMBROLIZUMAB
CHEMOTHERAPY
Publication Status
Published
Date Publish Online
2021-09